Regencell Bioscience Holdings (RGC) Common Equity (2020 - 2025)

Regencell Bioscience Holdings' Common Equity history runs 6 years deep, the most recent figure standing at $1.2 million for Q4 2025.

• Quarterly Common Equity changed N/A year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (changed N/A YoY) and the FY2025 annual result came in at $4.9 million, down 40.86% from the prior year.
• Common Equity was $1.2 million for Q4 2025 at Regencell Bioscience Holdings, down from $4.9 million in the prior quarter.
• Across five years, Common Equity topped out at $17.1 million in Q2 2022 and bottomed at -$4.0 million in Q2 2021.
• A 5-year average of $6.6 million and a median of $6.5 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2021 — Common Equity slumped 50.8% — and 2022, when it surged 527.27%.
• Regencell Bioscience Holdings' Common Equity stood at -$4.0 million in 2021, then jumped by 527.27% to $17.1 million in 2022, then slipped by 29.81% to $12.0 million in 2023, then tumbled by 31.45% to $8.2 million in 2024, then sank by 85.16% to $1.2 million in 2025.
• Business Quant data shows RGC's Common Equity at $1.2 million in Q4 2025, $4.9 million in Q2 2025, and $8.2 million in Q2 2024.